Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.

Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G.

Curr Oncol. 2012 Aug;19(4):202-8. doi: 10.3747/co.19.972.

PMID:
22876146
[PubMed]
Free PMC Article
2.

Protein kinase inhibitors in renal cell carcinoma.

Daste A, Grellety T, Gross-Goupil M, Ravaud A.

Expert Opin Pharmacother. 2014 Feb;15(3):337-51. doi: 10.1517/14656566.2014.869210. Epub 2013 Dec 16.

PMID:
24328606
[PubMed - in process]
3.

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.

Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E.

Clin Pharmacol Ther. 2012 Oct;92(4):503-10. doi: 10.1038/clpt.2012.136. Epub 2012 Sep 5.

PMID:
22948895
[PubMed - indexed for MEDLINE]
4.

Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.

Ferroni P, Della-Morte D, Palmirotta R, Rundek T, Guadagni F, Roselli M.

Curr Vasc Pharmacol. 2012 Jul;10(4):479-93. Review.

PMID:
22272903
[PubMed - indexed for MEDLINE]
5.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
[PubMed - indexed for MEDLINE]
6.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

PMID:
18669461
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN.

BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

PMID:
22212284
[PubMed - indexed for MEDLINE]
8.

Bevacizumab-induced hypertension: pathogenesis and management.

Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K.

BioDrugs. 2011 Jun 1;25(3):159-69. doi: 10.2165/11590180-000000000-00000. Review.

PMID:
21627340
[PubMed - indexed for MEDLINE]
9.

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.

Macfarlane R, Heng DY, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK.

Cancer. 2012 Jan 15;118(2):365-70. doi: 10.1002/cncr.26201. Epub 2011 Jun 29.

PMID:
21717427
[PubMed - indexed for MEDLINE]
Free Article
10.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
[PubMed - indexed for MEDLINE]
11.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
[PubMed - indexed for MEDLINE]
12.

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Albiges L, Salem M, Rini B, Escudier B.

Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006. Review.

PMID:
21763969
[PubMed - indexed for MEDLINE]
13.

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.

Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE.

Oncol Res Treat. 2014;37(3):136-41. doi: 10.1159/000360179. Epub 2014 Feb 21.

PMID:
24685918
[PubMed - in process]
Free Article
14.

Management of metastatic renal cell carcinoma in patients with poor prognosis.

Bullock A, McDermott DF, Atkins MB.

Cancer Manag Res. 2010 May 24;2:123-32.

PMID:
21188103
[PubMed]
Free PMC Article
15.

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J.

Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Review.

PMID:
21704448
[PubMed - indexed for MEDLINE]
16.

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ.

Eur J Cancer. 2011 Jun;47(9):1287-98. doi: 10.1016/j.ejca.2011.02.014. Epub 2011 Apr 8. Review.

PMID:
21481584
[PubMed - indexed for MEDLINE]
17.

Anti-angiogenic activity of melatonin in advanced cancer patients.

Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ.

Neuro Endocrinol Lett. 2001;22(1):45-7.

PMID:
11335879
[PubMed - indexed for MEDLINE]
18.

Vascular endothelial growth factor and bevacitumab in breast cancer.

Bando H.

Breast Cancer. 2007;14(2):163-73. Review.

PMID:
17485901
[PubMed - indexed for MEDLINE]
Free Article
19.

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Review.

PMID:
19954291
[PubMed - indexed for MEDLINE]
20.

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Schmidinger M, Bellmunt J.

Cancer Treat Rev. 2010 Aug;36(5):416-24. doi: 10.1016/j.ctrv.2010.01.003. Epub 2010 Feb 16. Review.

PMID:
20163917
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk